Sanofi: Sarclisa Combination Provides Unprecedented Median PFS In Relapsed Multiple Myeloma

PARIS (dpa-AFX) - French drug major Sanofi (SNYNF, SNY) said that Sarclisa (isatuximab) combination provided unprecedented median progression free survival in patients with relapsed multiple myeloma

Related Keywords

France ,Paris ,France General ,French , ,Drug Administration ,Sanofi ,Sarclisa ,Combination ,Rovides ,Unprecedented ,Comedian ,Relapsed ,Multiple ,Myeloma ,